At a glance
- Originator Unknown
- Developer Eli Lilly and Company; Nonindustrial source
- Class Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Graft-versus-host disease
Most Recent Events
- 19 Jun 2001 This compound is still in active development
- 18 Jun 2001 No-Development-Reported for Graft-versus-host disease in USA (Unknown route)
- 28 Oct 1998 Preclinical development for Graft-versus-host disease in USA (Unknown route)